Myriad Pharmaceuticals Newswire

Myriad Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Myriad Pharmaceuticals.

Results 1 - 20 of 459 in Myriad Pharmaceuticals

  1. Head-To-Head Analysis: Varex ImagingRead the original story w/Photo

    4 hrs ago | IntersportsWire

    VAREX IMAGING and Myriad Genetics are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability. This is a breakdown of recent ratings and target prices for VAREX IMAGING and Myriad Genetics, as reported by MarketBeat.com.

    Comment?

  2. State of Tennessee Treasury Department Decreases Position in Myriad Genetics, Inc.Read the original story w/Photo

    7 hrs ago | IntersportsWire

    State of Tennessee Treasury Department cut its holdings in shares of Myriad Genetics, Inc. by 1.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission . The firm owned 64,075 shares of the company's stock after selling 1,050 shares during the period.

    Comment?

  3. Myriad Genetics, Inc. (MYGN) Holdings Reduced by Principal Financial Group Inc.Read the original story w/Photo

    8 hrs ago | The Breeze

    Principal Financial Group Inc. reduced its position in Myriad Genetics, Inc. by 0.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 528,346 shares of the company's stock after selling 1,802 shares during the period.

    Comment?

  4. Myriad Genetics, Inc. (MYGN) Short Interest Down 12.9% in AugustRead the original story w/Photo

    Yesterday | The Breeze

    Myriad Genetics, Inc. was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 16,412,692 shares, a decrease of 12.9% from the August 15th total of 18,843,047 shares.

    Comment?

  5. Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Quarterly Sales of $182.22 MillionRead the original story w/Photo

    Monday | AmericanBankingNews.com

    Brokerages expect Myriad Genetics, Inc. to post sales of $182.22 million for the current fiscal quarter, according to Zacks Investment Research . Five analysts have issued estimates for Myriad Genetics' earnings, with the lowest sales estimate coming in at $181.80 million and the highest estimate coming in at $183.02 million.

    Comment?

  6. Myriad Genetics' (MYGN) Hold Rating Reaffirmed at Cowen and CompanyRead the original story w/Photo

    Sunday Sep 17 | AmericanBankingNews.com

    's stock had its "hold" rating reiterated by analysts at Cowen and Company in a research note issued on Sunday. They presently have a $25.00 target price on the stock.

    Comment?

  7. Varex Imaging (VREX) versus Myriad Genetics (MYGN) Financial ReviewRead the original story w/Photo

    Saturday Sep 16 | AmericanBankingNews.com

    Varex Imaging and Myriad Genetics are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership. 91.8% of Varex Imaging shares are held by institutional investors.

    Comment?

  8. Myriad Genetics Announces Positive Data Supporting New riskScore Test ...Read the original story

    Friday Sep 15 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors in Columbus, OH. We look forward to presenting our pioneering research at NSGC this year and bringing forward new innovations that are changing how a woman's risk of breast cancer is being managed and improving the lives of even more people, " said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.

    Comment?

  9. Myriad Genetics Announces Positive Data Supporting New riskScorea ...Read the original story

    Friday Sep 15 | Customer Interaction Solutions

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors in Columbus, OH. "We look forward to presenting our pioneering research at NSGC this year and bringing forward new innovations that are changing how a woman's risk of breast cancer is being managed and improving the lives of even more people," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.

    Comment?

  10. Myriad Genetics, Inc. (MYGN) Shares Sold by Pacad Investment Ltd.Read the original story w/Photo

    Friday Sep 15 | The Breeze

    Pacad Investment Ltd. reduced its stake in Myriad Genetics, Inc. by 73.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission . The institutional investor owned 6,400 shares of the company's stock after selling 18,000 shares during the period.

    Comment?

  11. Global Genetic Testing Market: Industry Review, Research, Statistics, and Growth to 2023Read the original story w/Photo

    Thursday Sep 14 | SBWire

    Market Synopsis of Global Genetic testing Market: Market Scenario: Genetic testing involves the use of laboratory methods to study the genes inherited from mother or father. These tests may be used to identify increased risks of health problems, to diagnose the mutations in the genes, to choose treatments, or to assess responses to treatment.

    Comment?

  12. Myriad Genetics To Present Three Studies At The 2017 Annual ConferenceRead the original story

    Tuesday Sep 12 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors Annual Conference to be held September 13-16, 2017, in Columbus, OH. Importantly, Myriad will present results from a study with 17,205 patients designed to validate a panel of single nucleotide polymorphisms across the entire human genome that are associated with increased breast cancer risk.

    Comment?

  13. Financial Comparison: Varex ImagingRead the original story w/Photo

    Tuesday Sep 12 | AmericanBankingNews.com

    Varex Imaging and Myriad Genetics are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, risk and dividends. 91.8% of Varex Imaging shares are owned by institutional investors.

    Comment?

  14. Myriad Genetics to Present Three Studies at the 2017 National Society ...Read the original story

    Tuesday Sep 12 | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors Annual Conference to be held September 13-16, 2017, in Columbus, OH. Importantly, Myriad will present results from a study with 17,205 patients designed to validate a panel of single nucleotide polymorphisms across the entire human genome that are associated with increased breast cancer risk.

    Comment?

  15. Prostate Cancer Awareness Month: Myriad Genetics working to educate...Read the original story w/Photo

    Monday Sep 11 | Medical News

    Eligible Patients Can Use the myRisk Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September. With 2.9 million men living with prostate cancer, it is now the second leading form of cancer in the United States, killing one man every 19 minutes.

    Comment?

  16. Hereditary Cancer Risk Assessment Is an Important Option for Prostate ...Read the original story

    Saturday Sep 9 | Newkerala.com

    SALT LAKE CITY, Sept. 9, 2017 : Myriad Genetics, Inc. , a leader in molecular diagnostics and personalized medicine, is working to educate the public about hereditary cancer risk assessment and testing during Prostate Cancer Awareness Month this September.

    Comment?

  17. Myriad Genetics, Inc. (MYGN) Receives Consensus Rating of "Hold" from AnalystsRead the original story w/Photo

    Saturday Sep 9 | AmericanBankingNews.com

    Myriad Genetics, Inc. has been given an average rating of "Hold" by the twelve research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company.

    Comment?

  18. Myriad Genetics, Inc. (MYGN) Trading Up 0.8%Read the original story w/Photo

    Saturday Sep 9 | Daily Political

    Myriad Genetics, Inc. 's share price traded up 0.8% on Thursday . The company traded as high as $33.20 and last traded at $32.82.

    Comment?

  19. Vascular Solutions (VASC) & Myriad Genetics (MYGN) Critical SurveyRead the original story w/Photo

    Friday Sep 8 | AmericanBankingNews.com

    Vascular Solutions and Myriad Genetics are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Myriad Genetics has higher revenue and earnings than Vascular Solutions.

    Comment?

  20. Varex Imaging (VREX) and Myriad Genetics (MYGN) Head-To-Head ReviewRead the original story w/Photo

    Friday Sep 8 | IntersportsWire

    Varex Imaging and Myriad Genetics are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends. 91.8% of Varex Imaging shares are held by institutional investors.

    Comment?